甘肃在医改试点城市率先推行药品采购“两票制”

2017-04-28 梁军 新华社

甘肃省决定在公立医院改革试点城市率先推行药品采购“两票制”,争取到2018年全面推开。

甘肃省决定在公立医院改革试点城市率先推行药品采购“两票制”,争取到2018年全面推开,从而压缩流通领域中间环节,降低药品虚高价格。

近日印发的《甘肃省公立医疗机构药品采购“两票制”实施方案(试行)》要求,全省医改试点城市率先推行“两票制”,三级公立医院于今年10月1日起落实“两票制”,二级公立医疗机构于新一轮药品集中采购中标结果执行起全面落实,争取到2018年全面推开药品采购“两票制”。

甘肃省明确,除国家实行特殊管理的麻醉药品、精神药品、医疗用毒性药品和放射性药品、中药饮片,甘肃省分类管理目录药品以及罕见病、特殊疾病等临床用量小的药品外,其他药品均执行“两票制”。

甘肃省要求,加强对配送企业和公立医疗机构执行“两票制”的监督检查,对索票(证)不严、“两票制”落实不到位、拖欠货款、有令不行的将通报批评,直至取消配送资格或追究相关人员责任。

“两票制”是指药品生产企业到流通企业开一次发票,流通企业到医疗机构开一次发票,是我国深化医药卫生体制改革的重要举措。目前,全国已有安徽、四川、湖南多地实施了药品采购“两票制”改革。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 tidiq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 wolongzxh
  6. [GetPortalCommentsPageByObjectIdResponse(id=1641564, encodeId=fc8b164156481, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Wed Dec 13 07:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941890, encodeId=53121941890db, content=<a href='/topic/show?id=d65e91e47aa' target=_blank style='color:#2F92EE;'>#试点城市#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91747, encryptionId=d65e91e47aa, topicName=试点城市)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Fri Dec 29 06:14:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286701, encodeId=36fb1286e01a0, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419533, encodeId=d728141953328, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532699, encodeId=ece6153269966, content=<a href='/topic/show?id=88f395665de' target=_blank style='color:#2F92EE;'>#采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95665, encryptionId=88f395665de, topicName=采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb312387914, createdName=wolongzxh, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537779, encodeId=1202153e77968, content=<a href='/topic/show?id=86f38e504fe' target=_blank style='color:#2F92EE;'>#药品采购#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87504, encryptionId=86f38e504fe, topicName=药品采购)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d5f12898837, createdName=zhaozuguo, createdTime=Sun Apr 30 10:14:00 CST 2017, time=2017-04-30, status=1, ipAttribution=)]

相关资讯

药监联手卫计委严查两票制执行 违规者将被取消资格

不按规定执行“两票制”要求的或弄虚作假的药品生产、经营企业,将被取消投标、中标和配送资格,并列入药品采购不良记录。

两票制落地后 13省开始大面积流通整治

伴随着“两票制”落地,新一轮的流通整治汹涌而来!大半个中国已开始严查!

490个药品价格被监测 需承诺两票制!

昨日(4月18日),宁夏药品采购中心发布《关于2016宁夏回族自治区公立医院直接挂网采购药品价格监测等有关事项的通知》,2017年1月23日-2月10日,该中心对2016年宁夏直接挂网采购药品进行了价格监测。由于春节放假等原因,部分企业未能及时填报药品监测价格。经研究,决定对未填报企业直接挂网采购的490个药品价格进行监测。

卫计委要求:公立医院落实“两票制”抓这些环节

4月19日,为加快推进公立医疗机构在药品采购环节推行“两票制”,国家卫生计生委在京召开专题工作座谈会。国家卫生计生委副主任曾益新强调,各地要以推动建立规范有序、协同配合、保障供应的药品流通政策环境为重点,积极创新监管方式,运用信息化等便捷手段推动落实“两票制”,指导公立医院做好“两票制”的具体事项。

国家卫计委要求:两票制6月底前出方案,验票是执行的重点!

4月19日,为加快推进公立医疗机构在药品采购环节推行“两票制”,国家卫生计生委在京召开专题工作座谈会。

安徽堵上两票制“漏洞”,药商变鸡肋

有420个进口药品被紧盯上了!安徽堵上两票制“漏洞”!